Over the last decade, the Division of Cancer Prevention and Control (DCPC) within the Centers for Disease Control and Prevention (CDC) has established an ovarian cancer research program. DCPC also currently funds two programmatic activities specifically related to ovarian cancer. This report provides a summary of the results and impact of these research and programmatic activities.
Get full access to this article
View all access options for this article.
References
1.
U.S. Cancer Statistics Working Group. United States Cancer Statisics, 1999–2006. Incidence and mortality web-based report. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention and National Cancer Institute, 2010.
2.
EhemanCR, PeipinsL, WynnMet al.Development of a public health research program for ovarian cancer. J Womens Health, 2006; 15:339–345.
3.
TriversKF, StewartSL, PeipinsL, RimSH, WhiteMC. Expanding the public health research agenda for ovarian cancer. J Womens Health, 2009; 18:1299–1305.
4.
MajorA, StewartSL. Celebrating 10 years of the National Comprehensive Cancer Control Program, 1998 to 2008. Prev Chronic Dis, 2009; 6:A133.
5.
WingoPA, JamisonPM, HiattRAet al.Building the infrastructure for nationwide cancer surveillance and control—A comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States)Cancer Causes Control, 2003; 14:175–193.
6.
GoodmanMT, HoweHL. Descriptive epidemiology of ovarian cancer in the United States, 1992–1997. Cancer, 2003; 97,Suppl 10:2615–2630.
7.
HallHI, TungKH, HotesJ, LoganP. Regional variations in ovarian cancer incidence in the United States, 1992–1997. Cancer, 2003; 97,Suppl 10:2701–2706.
8.
StewartSL, ThompsonTD, GermanRR, CardinezCJ, FriedmanC, WingoPA. Geographic patterns of gynecologic cancer incidence and mortality. J Clin Oncol, 2005; 23,Suppl:477S.
9.
StewartSL, KingJB, CardinezCJ, ThompsonTD, FriedmanC, WingoPA. Geographic patterns of breast and ovarian cancer incidence and mortality. Cancer Epidemiol Biomarkers Prev, 2004; 13:1868S.
10.
StewartSL, WikeJM, SabatinoSA. Recent declines in ovarian cancer incidence rates in the United States. Proc AACR Frontiers in Cancer Prevention Res, 2007; A53.
11.
CDC. Decline in breast cancer incidence—United States, 1999–2003. MMWR, 2007; 56:549–553.
12.
StewartSL, WikeJM, FosterSL, MichaudF. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol, 2007; 107:392–397.
13.
GershensonDM. Fallopian tube cancer: Stepchild or mother?Gynecol Oncol, 2007; 107:386–387.
14.
CrumCP, DrapkinR, MironAet al.The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol, 2007; 19:3–9.
15.
HallHI, JamisonP, WeirHK. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev, 2001; 10:995–999.
16.
RimSH, BerkowitzZ, PeipinsL. Ovarian as a subsequent primary among women cancer survivors, 1973–2004. Cancer Epidemiol Biomarkers Prev, 2008; 17:464.
17.
BerkowitzZ, RimSH, PeipinsL, StewartSL. Factors associated with survival time among women diagnosed with ovarian as an index cancer versus a subsequent primary. Am J Epidemiol, 2009; 169:S4.
18.
WarrenJL, KlabundeCN, SchragD, BachPB, RileyGF. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care, 2002; 40,Suppl 8:IV–18.
19.
RyersonAB, EhemanC, BurtonJet al.Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol, 2007; 109:1053–1061.
20.
WynnML, ChangS, PeipinsLA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. J Womens Health, 2007; 16:971–986.
21.
StewartSL, WikeJM, CressR, O'MalleyC, NelomsS, KahnAR, SchymuraMJ. Ovarian cancer treatment patterns and outcomes in the United States: a National Program of Cancer Registries Study. J Clin Oncol, 2006; 24,Suppl:15031.
BamiasA, PsaltopoulouT, SotiropoulouMet al.Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer, 2010; 116:1462–1468.
24.
StewartSL, ThompsonTD, WikeJMet al.Descriptive epidemiology, treatment, and survival of low-grade and high-grade serous adenocarcinoma of the ovary. Gynecol Oncol, 2009; 112:S24.
25.
StewartSL, WikeJM, CressRD, O'MalleyCD, KahnAR, SchymuraMJ. Treatment patterns and outcomes of ovarian cancer patients by histology, data from the National Program of Cancer Registries (NPCR) Patterns of Care Study. Proc North Am Assoc Central Cancer Registries, 2006; 04.
26.
RolnickSJ, JacksonJ, NelsonWWet al.Pain management in the last six months of life among women who died of ovarian cancer. J Pain Symptom Manage, 2007; 33:24–31.
27.
HerrintonLJ, Neslund-DudasC, RolnickSJet al.Complications at the end of life in ovarian cancer. J Pain Symptom Manage, 2007; 34:237–243.
28.
JacksonJM, RolnickSJ, CoughlinSSet al.Social support among women who died of ovarian cancer. Support Care Cancer, 2007; 15:547–556.
29.
GoffBA, MatthewsBJ, LarsonEHet al.Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer, 2007; 109:2031–2042.
PollardWE. Use of consumer panel survey data for public health communication planning: An evaluation of survey results. Am Statist Assoc Proc Section Health Policy Statist, 2002; 2720–2724.
32.
StewartSL, RimSH, GelbCA. Public and provider awareness and use of a CA-125 test for ovarian cancer. Cancer Prev Res, 2010; 3,Suppl 1:A25.
33.
U.S. Preventive Services Task Force. Screening for ovarian cancer, 2004. www.ahrq.gov/clinic/uspstf/uspsovar.htm
